About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spectral AI Provides 2023-2024 Annual Revenue Guidance

By: via GlobeNewswire

DALLAS, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today provided annual revenue guidance for the fiscal years ending December 31, 2023 and 2024 and highlighted plans and opportunities associated with the ongoing development and commercialization of its AI-Driven DeepView® Wound Imaging Technology for diabetic foot ulcers (“DFU”), burn and other indications.

The Company recently announced the largest contract in its history, an award from the U.S. Government valued at over $149.0 million, which brings the total U.S. Government awards to the Company since 2019 to over $246.0 million. With this contract in hand, the Company now has far greater visibility into its research and development revenues for 2023 and 2024 and is pleased to provide this information to the Company’s shareholders.

Financial Guidance

  • Research & Development Revenue (“Revenue”) for FY2023 is expected to approximate $17.4 million
  • Revenue for FY2024 is expected to approximate $28.0 million

“We are on the cusp of delivering a distinct, cutting-edge AI-driven wound healing assessment platform with the potential to significantly improve the current standard of care across multiple indications,” said Wensheng Fan, CEO of Spectral AI. “As we continue to advance our burn indication, we are as excited about the prospects for the use of DeepView® for DFU, an estimated $11.0 billion market that we believe is in dire need of a solution that provides clinicians with an immediate healing assessment for more accurate and timely diagnosis and therapeutic intervention. We intend to submit applications for FDA, UKCA, and CE mark approval for the DeepView® DFU indication, as well as for 3D wound measurement capabilities, in FY2024 subject to the completion of ongoing studies.”

The Company noted that the financial guidance for FY2024 does not reflect the material financial contributions it expects would result from the commercialization of DeepView® for DFU and 3D wound measurement following the receipt of necessary regulatory clearances. As previously disclosed, the Company has received regulatory approval for the DeepView SnapShot® device and the Company will now seek the approval of its integrated AI application to obtain both UKCA and FDA approval for the commercialization of the complete DeepView SnapShot® System in the United States and across the globe.

“We believe we are in the best position in our history to deliver significant value for patients dealing with acute and chronic wound conditions, physicians and health systems that are challenged with effectively and cost-efficiently managing these conditions, and, of course, our shareholders,” Mr. Fan concluded.

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.

Forward Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Contacts:
Investors:
Spectral AI
Christine Marks
VP Marketing and Commercialization
ir@spectral-ai.com 

The Equity Group
Devin Sullivan, Managing Director
dsullivan@equityny.com

Conor Rodriguez, Analyst
crodriguez@equityny.com 

Media:
Russo Partners
David Schull
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com 

Guillermo Ruiz, M.D., Ph.D.
Russo Partners
(646) 218-4604
guillermo.ruiz@russopartnersllc.com 


Primary Logo

More News

View More
Microsoft Stock Hits Stride in 2025—How Much More Can It Run?
Via MarketBeat
Topics Artificial Intelligence Retirement
Tickers MSFT
How Berkshire's OxyChem Buy Cements Its Long-Term Strength
Via MarketBeat
Tickers BRK BRK-A BRK-B OXY
Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t Worry
Via MarketBeat
Tickers OKLO
Rocket Lab's Electron: The Quiet Workhorse Powering Momentum
Via MarketBeat
Tickers RKLB
Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore
Via MarketBeat
Topics Artificial Intelligence
Tickers NOW
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.